LakeShore Biopharma Faces Nasdaq Delisting
Ticker: LSBWF · Form: 6-K · Filed: Sep 12, 2025 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | high |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, regulatory
TL;DR
Nasdaq wants to kick LakeShore Biopharma off the exchange, company fighting back.
AI Summary
LakeShore Biopharma Co., Ltd. announced on September 12, 2025, that it received a determination from The Nasdaq Stock Market LLC indicating that the company's securities would be delisted. The company intends to request a hearing with the Nasdaq Hearings Panel to review the determination.
Why It Matters
This delisting determination could significantly impact the liquidity and trading of LakeShore Biopharma's shares, potentially affecting investor confidence and access to capital.
Risk Assessment
Risk Level: high — Receiving a delisting determination from a major stock exchange like Nasdaq presents a significant risk to the company's continued public trading and market valuation.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- The Nasdaq Stock Market LLC (company) — Exchange issuing delisting determination
- Nasdaq Hearings Panel (company) — Body to review delisting determination
- YS Biopharma Co., Ltd (company) — Former company name
- YishengBio Co., Ltd (company) — Former company name
FAQ
What is the primary reason for LakeShore Biopharma's receipt of a delisting determination?
The filing does not explicitly state the specific reasons for the delisting determination, but it indicates that the company received the determination from The Nasdaq Stock Market LLC.
What action will LakeShore Biopharma take in response to the delisting determination?
LakeShore Biopharma intends to request a hearing with the Nasdaq Hearings Panel to review the determination.
When did LakeShore Biopharma receive the delisting determination?
The filing is dated September 12, 2025, and the press release announcing the delisting determination is included as an exhibit, implying the determination was received around this date.
What is the filing type and date?
This is a Form 6-K filed on September 12, 2025.
Has LakeShore Biopharma changed its name previously?
Yes, the company was formerly known as YS Biopharma Co., Ltd. (name change effective March 10, 2023) and prior to that, YishengBio Co., Ltd (name change effective September 12, 2022).
Filing Stats: 174 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2025-09-12 09:05:02
Filing Documents
- ea0257151-6k_lakeshore.htm (6-K) — 10KB
- ea025715101ex99-1_lakeshore.htm (EX-99.1) — 9KB
- 0001213900-25-087068.txt ( ) — 21KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release - LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: September 12, 2025 2